1887

Journal of Medical Microbiology logo

Volume 73, Issue 4

Characterization of invasive Group B isolates from Western Australian infants, 2004–2020 No Access

Abstract

Invasive Group B (GBS; ) remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis (IAP) has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.

Using whole-genome sequencing and phenotypic antimicrobial susceptibility testing, we characterized sterile-site GBS isolates recovered from Western Australian infants between 2004 and 2020. Characteristics were compared between three time periods: 2004–2008, 2009–2015 and 2016–2020.

A total of 135 isolates were identified. The proportion of serotype III (22.7 % in Period 1 to 47.9 % in Period 3, =0.04) and clonal complex 17 (13.6–39.6 %, =0.01) isolates increased over time. Overall coverage of vaccines currently being trialled was >95 %. No isolates were penicillin resistant (MIC>0.25 mg l), but 21.5 % of isolates had reduced penicillin susceptibility (MIC>0.12 mg l) and penicillin MIC increased significantly over time (=0.04). Clindamycin resistance increased over time to 45.8 % in the latest period.

Based on comprehensive characterization of invasive infant GBS in Western Australia, we found that coverage for leading capsular polysaccharide and surface protein vaccine candidates was high. The demonstrated changes in serotype and molecular type highlight the need for ongoing surveillance, particularly with regard to future GBS vaccination programmes. The reduced susceptibility to IAP agents over time should inform changes to antibiotic guidelines.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): capsular serotypes , GBS , Group B Streptococcus , infant , multi-locus sequence types , resistance , surface proteins and vaccine
Funding
This study was supported by the:
  • Wesfarmers Centre for Vaccination and Infectious Diseases (WCVID) Seed and Partnership Grant (Award 2021:1)
    • Principle Award Recipient: GingerHilpipre
© 2024 Crown Copyright
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001822
2024-04-03
2024-04-30
Loading full text...

Full text loading...

References

  1. ACOG Prevention of Group B Streptococcal Early-Onset Disease in Newborns; 2022 https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/02/prevention-of-group-b-streptococcal-early-onset-disease-in-newborns
  2. Kohli-Lynch M, Russell NJ, Seale AC, Dangor Z, Tann CJ et al. Neurodevelopmental impairment in children after Group B Streptococcal disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017; 65:S190–S199 [View Article] [PubMed]
     [Google Scholar]
  3. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH et al. Group B Streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15–20 [View Article] [PubMed]
     [Google Scholar]
  4. Nanduri SA, Petit S, Smelser C, Apostol M, Alden NB et al. Epidemiology of invasive early-onset and late-onset Group B Streptococcal disease in the United States, 2006 to 2015. JAMA Pediatr 2019; 173:224–233 [View Article]
     [Google Scholar]
  5. Daley AJ, Isaacs D. Australasian Study Group for Neonatal Infections Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. Pediatr Infect Dis J 2004; 23:630–634 [View Article] [PubMed]
     [Google Scholar]
  6. Braye K, Foureur M, de Waal K, Jones M, Putt E et al. Group B Streptococcal screening, intrapartum antibiotic prophylaxis, and neonatal early-onset infection rates in an Australian local health district: 2006-2016. PLoS One 2019; 14:e0214295 [View Article] [PubMed]
     [Google Scholar]
  7. Seale AC, Baker CJ, Berkley JA, Madhi SA, Ordi J et al. Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions. Vaccine 2019; 37:4877–4885 [View Article] [PubMed]
     [Google Scholar]
  8. Trials C. Identifier NCT03765073, Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine in Healthy Nonpregnant Women and Pregnant Women And Their Infants Bethesda, MD: ClinicalTrials.gov; 2018 https://clinicaltrials.gov/ct2/show/NCT03765073
  9. Minervax Product Pipeline Copenhagen, Denmark; 2021 https://www.minervax.com/product-pipeline
  10. Trials C. Identifier NCT05154578, Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women; 2021 https://clinicaltrials.gov/ct2/show/NCT05154578
  11. McGee L, Chochua S, Li Z, Mathis S, Rivers J et al. Multistate, population-based distributions of candidate vaccine targets, clonal complexes, and resistance features of invasive Group B Streptococci within the United States, 2015-2017. Clin Infect Dis 2021; 72:1004–1013 [View Article] [PubMed]
     [Google Scholar]
  12. Bianchi-Jassir F, Paul P, To K-N, Carreras-Abad C, Seale AC et al. Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine 2020; 38:6682–6694 [View Article] [PubMed]
     [Google Scholar]
  13. Zhao Z, Kong F, Zeng X, Gidding HF, Morgan J et al. Distribution of genotypes and antibiotic resistance genes among invasive Streptococcus agalactiae (Group B Streptococcus) isolates from Australasian patients belonging to different age groups. Clin Microbiol Infect 2008; 14:260–267 [View Article] [PubMed]
     [Google Scholar]
  14. Ko DW, Zurynski Y, Gilbert GL. GBS Study Group Group B Streptococcal disease and genotypes in Australian infants. J Paediatr Child Health 2015; 51:808–814 [View Article] [PubMed]
     [Google Scholar]
  15. Bartlett AW, Smith B, George CRR, McMullan B, Kesson A et al. Epidemiology of late and very late onset Group B Streptococcal disease: fifteen-year experience from two Australian tertiary pediatric facilities. Pediatr Infect Dis J 2017; 36:20–24 [View Article] [PubMed]
     [Google Scholar]
  16. Institute TCaLS Performance Standards for Antimicrobial Susceptibility Testing. M100-31, Table 31 Wayne, Pennsylvania: The Clinical and Laboratory Standards Institute; 2021
     [Google Scholar]
  17. Testing TECoAS Breakpoint Tables for Interpretation of MICs and Zone Diameters 2021
     [Google Scholar]
  18. Institute TCaLS Performance Standards for Antimicrobial Susceptibility Testing. M100-31, Table 2H-1: The Clinical and Laboratory Standards Institute 2021
     [Google Scholar]
  19. Inouye M, Dashnow H, Raven L-A, Schultz MB, Pope BJ et al. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 2014; 6:90 [View Article] [PubMed]
     [Google Scholar]
  20. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19:455–477 [View Article] [PubMed]
     [Google Scholar]
  21. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics 2013; 29:1072–1075 [View Article] [PubMed]
     [Google Scholar]
  22. Creti R, Fabretti F, Orefici G, von Hunolstein C. Multiplex PCR assay for direct identification of Group B Streptococcal alpha-protein-like protein genes. J Clin Microbiol 2004; 42:1326–1329 [View Article] [PubMed]
     [Google Scholar]
  23. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J et al. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep 2021; 11:12728 [View Article] [PubMed]
     [Google Scholar]
  24. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 2018; 3:124 [View Article] [PubMed]
     [Google Scholar]
  25. Jolley KA, Maiden MCJ. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinform 2010; 11:595 [View Article] [PubMed]
     [Google Scholar]
  26. Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res 2016; 44:W242–5 [View Article] [PubMed]
     [Google Scholar]
  27. Organization WH Group B Streptoccocus infection causes an estimated 150,000 preventable stillbirths and infant deaths every year Geneva, Switzerland: World Health Organization; 2017 https://www.who.int/news/item/05-11-2017-group-b-streptococcus-infection-causes-an-estimated-150-000-preventable-stillbirths-and-infant-deaths-every-year
  28. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AKM et al. Group B Streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012; 379:547–556 [View Article] [PubMed]
     [Google Scholar]
  29. O’Sullivan CP, Lamagni T, Patel D, Efstratiou A, Cunney R et al. Group B Streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study. Lancet Infect Dis 2019; 19:83–90 [View Article] [PubMed]
     [Google Scholar]
  30. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18:441–451 [View Article] [PubMed]
     [Google Scholar]
  31. Furfaro LL, Nathan EA, Chang BJ, Payne MS. Group B Streptococcus prevalence, serotype distribution and colonization dynamics in Western Australian pregnant women. J Med Microbiol 2019; 68:728–740 [View Article] [PubMed]
     [Google Scholar]
  32. Jamrozy D, Bijlsma MW, de Goffau MC, van de Beek D, Kuijpers TW et al. Increasing incidence of group B Streptococcus neonatal infections in the Netherlands is associated with clonal expansion of CC17 and CC23. Sci Rep 2020; 10:9539 [View Article] [PubMed]
     [Google Scholar]
  33. Zhou Y, Wang L-Q, Yan Q, Lee C-C, Hsu M-H et al. Genomic analysis of Group B Streptococcus from neonatal sepsis reveals clonal CC17 expansion and virulence- and resistance-associated traits after intrapartum antibiotic prophylaxis. Clin Infect Dis 2022; 75:2153–2160 [View Article] [PubMed]
     [Google Scholar]
  34. Tazi A, Plainvert C, Anselem O, Ballon M, Marcou V et al. Risk factors for infant colonization by hypervirulent CC17 Group B Streptococcus: toward the understanding of late-onset disease. Clin Infect Dis 2019; 69:1740–1748 [View Article] [PubMed]
     [Google Scholar]
  35. Gabrielsen C, Mæland JA, Lyng RV, Radtke A, Afset JE. Molecular characteristics of Streptococcus agalactiae strains deficient in alpha-like protein encoding genes. J Med Microbiol 2017; 66:26–33 [View Article] [PubMed]
     [Google Scholar]
  36. Meehan M, Cunney R, Cafferkey M. Molecular epidemiology of Group B Streptococci in Ireland reveals a diverse population with evidence of capsular switching. Eur J Clin Microbiol Infect Dis 2014; 33:1155–1162 [View Article] [PubMed]
     [Google Scholar]
  37. Hayes K, O’Halloran F, Cotter L. A review of antibiotic resistance in Group B Streptococcus: the story so far. Crit Rev Microbiol 2020; 46:253–269 [View Article] [PubMed]
     [Google Scholar]
  38. Metcalf BJ, Chochua S, Gertz RE, Hawkins PA, Ricaldi J et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 2017; 23:574 [View Article] [PubMed]
     [Google Scholar]
  39. Dahesh S, Hensler ME, Van Sorge NM, Gertz RE Jr, Schrag S et al. Point mutation in the Group B Streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 2008; 52:2915–2918 [View Article] [PubMed]
     [Google Scholar]
  40. Seki T, Kimura K, Reid ME, Miyazaki A, Banno H et al. High isolation rate of MDR Group B Streptococci with reduced penicillin susceptibility in Japan. J Antimicrob Chemother 2015; 70:2725–2728 [View Article] [PubMed]
     [Google Scholar]
  41. Sigaúque B, Kobayashi M, Vubil D, Nhacolo A, Chaúque A et al. Invasive bacterial disease trends and characterization of Group B Streptococcal isolates among young infants in southern Mozambique, 2001-2015. PLoS One 2018; 13:e0191193 [View Article] [PubMed]
     [Google Scholar]
  42. Kobayashi M, McGee L, Chochua S, Apostol M, Alden NB et al. Low but Increasing prevalence of reduced beta-lactam susceptibility among invasive Group B Streptococcal isolates, US population-based surveillance, 1998-2018. Open Forum Infect Dis 2021; 8:ofaa634 [View Article] [PubMed]
     [Google Scholar]
  43. Garland SM, Cottrill E, Markowski L, Pearce C, Clifford V et al. Antimicrobial resistance in Group B Streptococcus: the Australian experience. J Med Microbiol 2011; 60:230–235 [View Article] [PubMed]
     [Google Scholar]
  44. Stewart AG, Burnard D, Sowden D, McMillan D. Whole genome sequencing for antimicrobial resistance mechanisms, virulence factors and clonality in invasive Streptococcus agalactiae blood culture isolates recovered in Australia. Pathology 2020; 52:694–699 [View Article] [PubMed]
     [Google Scholar]
  45. Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med 2020; 180:745–752 [View Article] [PubMed]
     [Google Scholar]
  46. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA 2019; 321:188–199 [View Article] [PubMed]
     [Google Scholar]
  47. Papp JR, Rowlinson M-C, O’Connor NP, Wholehan J, Razeq JH et al. Accuracy and reproducibility of the Etest to detect drug-resistant Neisseria gonorrhoeae to contemporary treatment. J Med Microbiol 2018; 67:68–73 [View Article]
     [Google Scholar]
  48. Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Boulet B et al. Multisite reproducibility of etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 2000; 38:656–661 [View Article] [PubMed]
     [Google Scholar]
  49. Matsubara K, Nishiyama Y, Katayama K, Yamamoto G, Sugiyama M et al. Change of antimicrobial susceptibility of Group B Streptococci over 15 years in Japan. J Antimicrob Chemother 2001; 48:579–582 [View Article] [PubMed]
     [Google Scholar]
  50. Khademi F, Sahebkar A. Group B Streptococcus drug resistance in pregnant women in Iran: a meta-analysis. Taiwan J Obstet Gynecol 2020; 59:635–642 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001822
Loading
Characterization of invasive Group B Streptococcus isolates from Western Australian infants, 2004–2020
J. Med. Microbiol. 73, 001822 (2024); https://doi.org/10.1099/jmm.0.001822
/content/journal/jmm/10.1099/jmm.0.001822
/content/journal/jmm/10.1099/jmm.0.001822
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error